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1607-551X/Copyright ª 2014, KaohsiuAbstract Alcoholic liver cirrhosis is a severe form of alcohol-related liver damage. More than
95% of heavy drinkers develop a fatty liver, but only 35% of them develop cirrhosis. We postu-
late that genetic factors may play a role in this difference. Genetic polymorphisms of the cyto-
kine genes may influence Kupffer cells cytokine genes expression. In this study, we evaluated
the promoter polymorphisms of interleukin (IL) 1b, IL 6, IL 10, and tumor necrosis factor alpha
(TNFa) and aimed to clarify the association between the polymorphisms and the disease. Forty
alcoholic patients with liver cirrhosis and 64 healthy volunteers were included in our investi-
gation. Genotyping on IL 1b e511 T>C, IL 6 e572 G>C, IL 10 e819 C>T, IL 10 e1082 G>A,
and TNFa e308 G>A was done. Another 36 patients with recurrent alcoholic pancreatitis were
included as an additional control group. Genotyping on IL 10 e819 C>T and IL 10 e1082 G>A
was done. The polymorphisms on IL 1 and IL 6 showed no significant association. The p value for
TNFa e308 G>A was 0.028 in comparison with healthy volunteers. Although the p value was
less than 0.05, it did not reach significance after Bonferroni correction. The p values for IL
10 e819 C>T and IL 10 e1082 G>A were respectively 0.031 and 0.026 in healthy volunteers
and 0.028 and 0.023 in the alcoholic pancreatitis group. The results also did not reach signif-
icance after Bonferroni correction. Among the participants with the GCC haplotype, healthy
volunteers had p Z 0.027 (p < 0.05) and an odds ratio (OR) of 0.124 [confidence interval
(95%) CI, 0.015e0.997], whereas the alcoholic pancreatitis group had p Z 0.023 (p < 0.05)
and an OR of 0.106 (95% CI, 0.012e0.912). The odds ratio of people having one ATA haplotypeeclare no conflicts of interest.
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292 A.-M. Yang et al.was 6.233 (95% CI, 0.739e52.547) in healthy volunteers and 6.588 (95% CI, 0.727e59.679) in the
alcoholic pancreatitis group; the corresponding rate was 10.521 (95% CI, 1.252e88.440) and
12.833 (95% CI 1.408e117.008) for people with two ATA haplotypes. The p values in these
groups were 0.031 (p < 0.05) and 0.028 (p < 0.05), respectively. The presence of a GCC haplo-
type could have protective effect against alcoholic liver disease, whereas the presence of an
ATA haplotype could predispose carriers to the disease. The IL 10 promoter haplotype is asso-
ciated with alcoholic liver cirrhosis in Taiwanese patients.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Alcoholism is a major cause of chronic liver disease world-
wide [1] and contributes up to 48% of cirrhosis-related
deaths in the United States [2]. The spectrum of alcohol-
related liver injury ranges from simple fatty liver to more
severe forms of liver damage such as liver fibrosis and
cirrhosis, and even superimposed with hepatocellular
carcinoma.
More than 95% of heavy drinkers develop a fatty liver,
but only up to 35% of these individuals develop more severe
forms of alcoholic liver disease [3]. This indicates that
other factors may be involved. Several risk factors for
alcoholic liver disease have been identified: sex, obesity,
drinking patterns, dietary factors, genetic factors, and
cigarette smoking [4e6]. Factors such as female gender,
obesity, and drinking patterns have been well documented
[7,8]. Genetic factors may also influence susceptibility to
advanced alcoholic liver disease; however, only scanty data
are available on this topic.
Themechanism of alcohol liver damage initiates from the
activation of innate immunity in the sinusoid by endotoxins
such as lipopolysaccharides from portal circulation. The
toxin is produced by Gram-negative bacteria in the intestine
and translocates to portal circulation owing to increased
intestinal permeability after excess alcohol consumption [9].
This stimulation initiates and promotes oxidative stress and
inflammatory process via interactionwith Kupffer cells in the
sinusoid [10]. The proinflammatory cytokines released from
Kupffer cells may further activate stellate cells and cause
liver fibrosis. Therefore, inflammatory responses originating
from Kupffer cells may play an important role in the process
of alcoholic liver cirrhosis [11]. Hence, the different in-
flammatory responses of immune cells and following cyto-
kine expression in the liver may be critical to the
pathogenesis of alcoholic liver cirrhosis.
Therefore, we postulate that the gene expression of
these cytokines of the Kupffer cells may be responsible for
the immune response and subsequent fibrosis. Because the
major cytokines secreted by Kupffer cell are TNFa, IL 1, IL
6, IL 10, PDGF, MCP 1, and TGF-b [10,11], we selected four
cytokines with reported promoter polymorphisms for
further genotyping. In this study, we evaluated the associ-
ation of promoter polymorphisms on IL 10: e1082 G>A
(rs1800896), e819 C>T (rs180871), e592 C>A (rs1800872),
IL 6: e572 G>C (rs1800796), IL 1b: e511 T>C (rs 1143627),
as well as TNFa: e308 G>A (rs1800629) in patients with
alcoholic liver cirrhosis.Methods
Patients
We recruited 40 ethnically Taiwanese Han patients with
continuous alcohol consumption and liver cirrhosis and 64
adult healthy volunteers without regular alcohol consump-
tion. To represent heavy drinkers without liver cirrhosis,
another group of 36 patients with continuous alcohol con-
sumption who experienced episodes of acute pancreatitis
more than twice but without liver cirrhosis were included
as an additional control group; in this group, interleukin (IL)
10 promoter polymorphisms were genotyped.
People with positive hepatitis C antibody, hepatitis B
surface antigen, and any other liver diseases were
excluded. The definition of liver cirrhosis called for patients
with (1) cirrhotic liver parenchyma on ultrasonography and
(2) endoscopically confirmed esophageal or gastric varices,
or (3) with splenomegaly on ultrasonography or computed
tomography. The definition of continuous alcohol drinking
was ingestion of >60 g/day of alcohol for more than
10 years in men and >20 g/day for more than 10 years in
women [12].
The information on the amount of alcohol consumption
was acquired by individual history taking. This study was
approved by the Institutional Review Board of En Chu Kong
Hospital, New Taipei City, Taiwan, and a written informed
consent was obtained from each participant.Genotyping
About 2 mL of peripheral blood was drawn from patients
with alcoholic liver cirrhosis, recurrent acute pancreatitis,
and healthy controls. Genomic DNA was extracted from
whole blood using the standard spin-column method
(NucleoSpin Blood, Macherey-Nagel, Du¨ren, Germany).
Genotyping of IL 1b e511 T>C, and IL 6 ef572 G>C was
carried out using polymerase chain reaction (PCR) with
restriction fragment length polymorphism [13,14]. Geno-
typing of IL 10 -819 C>T and TNFa -308 G>A was carried
out using ambulatory refractory mutation system-PCR
[15]. Genotyping of IL 10 e1082 G>A was done using
bidirectional allele-specific amplification [16]. Because IL
10 e819 C>T is in complete linkage disequilibrium with IL
10 e592 C>A, genotyping was only done on IL 10 e819
C>T [17]. The methods of genotyping are summarized in
Table 1.
Table 1 Methods of genotyping.
Loci Method Primers and restriction enzyme
IL 1B e511 T>C
(rs1143627)
PCR-RFLP 50-TGGCAT TGATCT GGT TCATC-30
50-GTTTAGGAATCTTCCCACTT-30
Restriction enzyme: AvaI
IL 6 e572 G>C
(rs1800796)
PCR-RFLP 50-GAGACGCCTTGAAGTAACTG-30
50-AACCAAAGATGTTCTGAACTGA-30
Restriction enzyme: BsrBI
IL 10 e819 C>T
(rs1800871)
ARMS-PCR 50-AGGATGTGTTCCAGGCTCCT-30
50-CCCTTGTACAGGTGATGTAAC-30
50-ACCCFFGTACAGGTGATGTAAT-30
IL 10 e1082 G>A
(rs1800896)
Bidirectional
allele specific
amplification
50-TTTCCAGATATCTGAAGAAGTCCTG-30
50-AACACTACTAAGGCTTCTTTGGGTA-30
50-TCTAAAGTTTAAAAGATGGGGTGGA-30
50-CTCTTACCTATCCCTACTTCCCGC-30
TNFa e308 G>A
(rs1800629)
ARMS-PCR 50-TCTCGGTTTCTTCTCCATCG-30
50-ATAGGTTTTGAGGGGCATGG-30
50-AATAGGTTTTGAGGGGCATGA-30
Internal control primers for ARMS-PCR: 50-GCCTTCCCAACCATTCECTTA-30 50-TCACGGATTTCAGTTGTGTTTC-30.
ARMS-PCRZ ambulatory refractory mutation system-polymerase chain reaction; PCR-RFLPZ polymerase chain reaction with restriction
fragment length polymorphism.
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The genotype distribution in the controls was compatible
with the HardyeWeinberg equilibrium. For the comparison
of the genotype difference between patients and controls,
Chi square test was used, and Fisher’s exact test was used if
any predicted value was <5.
Results
Polymorphism frequency
The caseecontrol comparison of the genotype of IL 1b e511
T>C and IL 6 e572 G>C showed p Z 0.44 and p Z 0.94,
respectively, in comparison to the healthy control group.
Both p values are far greater than 0.05.
On IL 10 e819 C>T, the cirrhotic-healthy control com-
parison p Z 0.031 (Fisher’s exact test). Using the CC ge-
notype as the reference genotype, the cirrhotic-healthy
control odds ratio (OR) of the CT genotype was 6.233 [95%
confidence interval (CI), 0.739e52.547] and was 10.521
(95% CI, 1.252e88.440) in the TT genotype. In the alcoholic
pancreatitis control group, the cirrhotic-pancreatitis com-
parison p Z 0.028 (Fisher’s exact test). The cirrhotic-
pancreatitis control OR of the CT genotype was 7.0 (95%
CI, 0.775e63.206) and was 12.83 (95% CI, 1.408e117.01) in
the TT genotype.
On IL 10 -1082 A>G, the AA genotype was 82.8%, AG was
17.2%, and GG was 0% in healthy controls; in cirrhotic pa-
tients, the corresponding values were 97.5%, 2.5%, and 0%,
respectively. The cirrhotic-healthy control comparison
p Z 0.026 (Fisher’s exact test). The cirrhotic-healthy con-
trol OR of having a G allele was 0.124 (95% CI,
0.015e0.997). In the alcoholic pancreatitis control group,
there was also no patient with a GG genotype. The
cirrhotic-pancreatitis comparison pZ 0.023 (Fisher’s exact
test). The cirrhotic-pancreatitis control OR of having a Gallele was 0.106 (95% CI, 0.013e0.912). The results of
alcoholic pancreatitis in this locus were similar to those of
healthy controls.
As far as TNFa-308 G>A is concerned, the GG genotype
was 87.5%, the GA genotype was 12.5%, and AA was 0% in
healthy controls; in patients, the corresponding values
were 70%, 30%, and 0%, respectively. The p value was 0.028
(Chi square test). The caseecontrol odd’s ratio of having an
A allele was 3.0 (95% CI, 1.100e8.179).
Among the polymorphisms tested, polymorphisms on IL
1b and IL 6 were not statistically significant. The cirrhotic-
healthy control comparison p values of polymorphisms on IL
10 and TNFa were all less than 0.05 and so was the
cirrhotic-pancreatitis control comparison p value on IL 10.
However, because five polymorphisms were tested, Bon-
ferroni correction (a multiple testing correction) had to be
considered, and consequently the threshold of significance
became 0.01. Therefore, these three polymorphisms were
not considered significant despite the raw p < 0.05. These
data are summarized in Table 2.IL 10 haplotype analysis
In further haplotype analysis, because of the marked link-
age disequilibrium, there were three haplotypes of the IL
10 e1082 A>G, e819C>T, and e592C>A: ACC (H1), ATA
(H2), and GCC (H3). The haplotypes could be easily iden-
tified in each participant without ambiguous biphasing [17].
As in Table 3, we presumed that each haplotype was
dominant separately and found that the presence of H3 and
H2 haplotypes was statistically significant.
In people with one H3 haplotype (the H3/H3 diplotype is
not found in this study), the cirrhotic-healthy control
comparison p Z 0.027 (p < 0.05) and the cirrhotic-healthy
control OR was 0.124 (95% CI, 0.015e0.997), whereas the
cirrhotic-pancreatitis control comparison p Z 0.023
(p < 0.05) and the cirrhotic-pancreatitis control OR was
Table 2 Analysis of the cytokine promoter polymorphism.
Loci Alcoholic liver
cirrhosis (n Z 40)
Healthy control
(n Z 64)
Alcoholic acute
pancreatitis
(n Z 36)
c2 or Fisher’s
exact test)
Referent allele,
OR (95% CI)
IL 1b e511
T>C
Genotype
TT 5 (12.5) 4 (6.25) d 0.44 1
TC 12 (30) 17 (26.6) 0.565
(0.125e2.552)
CC 23 (57.5) 43 (67.15) 0.428
(0.105e1.751)
Allele, frequency
T 0.275 0.195 d 0.233 1.559
(0.765e3.17)
C 0.725 0.805 1
IL 6 e572
G>C
Genotype
GG 2 (5) 3 (4.7) 0.94 1
GC 15 (37.5) 22 (35.11) d 1.023
(0.152e6.877)
CC 23 (57.5) 39 (60.19) 0.885
(0.137e5.693)
Allele, frequency
G 0.238 0.219 d 0.865 1.112
(0.538e2.265)
C 0.762 0.781 1
IL 10 e819
C>T
Genotype ealthy 0.031 1
CC 1 (2.5) 11 (17.2) 7 (19.5) 6.233
(0.739e52.547)
10.521 (1.252e88.440)
CT 17 (42.5) 30 (46.9) 17 (47.2) creatitis 0.028 1
TT 22 (55) 23 (35.9) 12 (33.3) 7.0
(0.775e63.206)
12.83
(1.408e117.01)
Allele, frequency ealthy 0.016 0.457
(0.230e0.883)
C 0.238 0.406 0.431 1
T 0.762 0.594 0.569 creatitis 0.015 0.412
(0.206e0.825)
1
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IL 10 associated with alcoholic liver cirrhosis 2950.106 (95% CI, 0.012e0.912). This result indicated that
people with H3 haplotype may be less likely to develop
alcoholic liver disease. As far as H2 is concerned, in
cirrhotic-healthy control comparison, the caseecontrol OR
of people without any H2 haplotype to people having one
H2 haplotype was 6.233 (95% CI, 0.739e52.547), and the
corresponding value was 10.521 (95% CI, 1.252e88.440) in
people with two H2 haplotypes. Also, the p value in this
group was 0.031 (p < 0.05). In cirrhotic-pancreatitis control
comparison, the OR of people without an H2 haplotype to
people with one H2 haplotype was 10.521 (95% CI,
1.252e88.44), and this was 12.833 (95% CI, 1.408e117.008)
in people with two H2 haplotypes; p Z 0.028 (p < 0.05).
This result suggests that people with H2 haplotypes may be
prone to develop alcoholic liver cirrhosis. As shown in
Table 4, H2/H2 diplotypes accounted for 55% in alcoholic
liver cirrhosis patients but only 34.38% in healthy controls
and 33.3% in alcoholic pancreatitis. In patients with alco-
holic liver cirrhosis, only 2.5% had H3 haplotype, but this
figure goes up to 17.15% in healthy controls and 19.4% in
alcoholic pancreatitis control. As for haplotype fre-
quencies, the presence of H1 was 22.5% in cirrhotic pa-
tients, 32% in healthy controls, and 33.3% in alcoholic
pancreatitis controls. The presence of H2 was 76.25% in
cirrhotic patients, 59.4% in healthy controls, and 57% in
alcoholic pancreatitis controls. Finally, the presence of H3
accounted for 1.25% in cirrhotic patients, 8.6% in healthy
controls, and 9.7% in alcoholic pancreatitis control (Table
3). The distribution of haplotype frequencies was also sta-
tistically significant in both healthy controls and alcoholic
pancreatitis controls (p Z 0.014 and p Z 0.011, respec-
tively). These results implied that the presence of the H3
haplotype could have a protective effect against alcoholic
liver disease, whereas the H2 haplotype could predispose
carriers to the disease. The results were consistent in both
control groups, suggesting that the polymorphism of the
haplotype was unique to alcoholic liver cirrhosis, and did
not reflect the stimulation of alcohol.Discussion
Alcoholism-induced problems are more serious than liver
diseases. It may relate to several types of cancer, unin-
tentional injuries both in the workplace and on the road,
domestic and social violence, broken marriages, and
damaged social and family relationships [18]. Although
abstinence has been proved to be the best method of
treatment [19], the 1-year relapse rate was found to range
from 67% to 81%, which shows the high possibility of
recurrence [20]. As far as treatment is concerned, medical
treatments for alcoholic liver disease and alcoholism itself
are suboptimal. Given the high recurrent rate of alcoholism
and lack of adequate medical treatment, a thorough un-
derstanding of the disease mechanism and risk factors
merits more efforts.
Among the complications of alcoholism, advanced liver
disease is frequently encountered in the clinical setting and
management of this disease is difficult. So far, the mech-
anism of the severe form of alcoholic liver disease has been
proposed as a “guteliver axis” theory: excess alcohol con-
sumption may increase the permeability of the intestines,
Table 3 Analysis of IL 10 haplotype.
Haplotype Diplotype Alcoholic liver 
cirrhosis
Healthy 
control
Alcoholic 
acute 
pancreatitis
p (Fisher’s exact 
test)
Referent allele OR (95% CI)
Haplotype 1 
(ACC)
other/other 23 (57.5%) 30 (46.9%) 18 (50.0%)
Healthy
0.25
Pancreatitis 
0.126
1
0.773 (0.339, 1.760)
0.186 (0.021, 1.623)
1
1.044 (0.396, 2.752)
0.13 (0.014, 1.181)
other/H1 16 (40.0%) 27 (42.2%) 12 (33.3%)
H1/H1 1 (2.5%) 7 (10.9%) 6 (16.7%)
Haplotype 2 
(ATA)
other/other 1 (2.5%) 11 (27.5%) 7 (19.5%) Healthy 
0.031
Pancreatitis 
0.028
1
6.233 (0.739, 52.547)
10.521 (1.252, 88.44)
1
6.588 (0.727, 59.679)
12.833 (1.408, 117.008)
other/H2 17 (42.5%) 30 (46.9%) 17 (47.2%)
H2/H2 22 (55.0%) 23 (25.6%) 12 (33.3%)
Haplotype 3 
(GCC)
other/other 39 (97.5%) 53 (82.8%) 29 (80.6%) Healthy
0.027
1
0.124 (0.015, 0.997)
other/H3 1 (2.5%) 11 (17.2%) 7 (19.4%) Pancreatitis
0.023
1
0.106 (0.012, 0.912)
H3/H3 0 0 0 –
Haplotype frequency
ACC (H1)
ATA (H2)
GCC (H3)
18 (22.5%) 41 (32.0%) 24 (33.3%) Healthy 
0.014
Pancreatitis 
0.011
1
1.828 (0.956, 3.497)
0.207 (0.025, 1.727)
1
1.984 (0.958, 4.109)
0.191 (0.022, 1.689)
61 (76.3%) 76 (59.4%) 41 (57.0%)
1 (1.25%) 11 (8.6%) 7 (9.7%)
*p values and odds ratios with significance are in bold type.
296 A.-M. Yang et al.and endotoxins generated by Gram-negative bacteria
translocate to the portal vein and activate an immune
response in the sinusoid [9]. According to this theory, the
innate immune response of the Kupffer cells is the starting
point of the subsequent inflammatory cascade. Kupffer
cells may generate several sorts of cytokines and mediate
the response by them. In the initial stage of this study, we
only included healthy individuals as the control population.
However, a question was raised as to whether the variation
in cytokine expression between normal individuals and
alcoholic cirrhotic patients may reflect the stimulation of
alcohol or may be regarded as secondary to histological
liver damage. To clarify this point, we added a group of
patients with continuous alcohol consumption and recur-
rent pancreatitis but had no liver cirrhosis. Because only ILTable 4 Analysis of IL 10 diplotype.
Diplotype Alcoholic liver
cirrhosis
Healthy
control
Alcoholic
pancreatitis
p (Fi
H1/H1 1 (2.5) 7 (10.9) 6 (16.7) He
H1/H2 16 (40) 24 (37.5) 11 (30.5)
H1/H3 0 4 (6.3) 1 (2.8)
H2/H2 22 (55) 22 (34.4) 12 (33.3) Panc
H2/H3 1 (2.5) 7 (10.9) 6 (16.7)
H3/H3 0 0 0
Data are presented as n (%), unless otherwise indicated.
H1 Z ACC; H2 Z ATA; H3 Z GCC.10 haplotype was statistically significant in this study, we
genotyped IL 10 promoter polymorphism on these patients.
The results of this additional test showed that the allele
frequency of IL 10 promoter polymorphism in alcoholic
pancreatitis patients was very similar to that in healthy
controls. This may reflect that the haplotype polymorphism
may be unique in alcoholic cirrhotic patients.
Among the cytokines, TNFa plays a pivotal role in
inflammation; it induces the expression of other proin-
flammatory molecules, chemotactic cytokines, and adhe-
sion factors that cause liver damage [21]. Moreover, TNFa
has been reported to be important in the pathogenesis of
certain diseases such as asthma, systemic lupus erythe-
matosus, and rheumatoid arthritis [22e24]. A meta-analysis
published in 2009 concerning the association of TNFasher’s exact
test)
Referent diplotype OR (95% CI)
Healthy Pancreatitis
althy 0.054 1 1
4.667 (0.523e1.64) 8.727 (0.918e82.959)
NA NA
reatitis 0.012 7 (0.794e61.741) 11 (1.182e102.38)
1 (0.052e19.36) 1 (0.05e19.963)
NA NA
IL 10 associated with alcoholic liver cirrhosis 297promoter e308G>A polymorphism with alcoholic liver dis-
ease, claimed no significant association [25] despite the A
allele having been reported to be with higher TNFa
expression [26]. However, while reviewing the meta-
analysis, we found that most results of the previous
studies were conflicting. As shown in our study, although
the p value was low, it was still statistically nonsignificant.
Despite the conflicting result, two anti-TNF a agents had
been studied for therapy of alcoholic hepatitis: infliximab
and etanercept. Despite the encouraging results in several
preliminary studies [27e29], subsequent large-scale studies
showed no significant benefit of both agents and cautioned
that they should not be used clinically [30,31].
By contrast, stimulation of Kupffer cells may also pro-
duce hepatoprotective cytokine IL 6 and anti-inflammatory
cytokine IL 10 [32]. It has been reported that IL 6 may
ameliorate alcoholic liver damage through the activation of
STAT3 (signal transducer and activator of transcription 3),
and downregulate lipogenic genes and upregulate b-oxida-
tion genes in the liver [33]. However, no association be-
tween IL 6 promoter polymorphism and alcoholic liver
damage was found in the literature. Among the promoter
polymorphisms in IL 6, IL 6 e174 G>C (rs1800795) has been
widely studied; however, this polymorphism does not seem
to exist in Asians in the dbSNP database. We tested another
polymorphism on IL 6 e572 G>C, which is more frequently
found among Asians, but still found no significant associa-
tion. We also tested IL 1b e511 T>C polymorphism because
it has been reported to be associated with reflux esopha-
gitis and may be helpful in maintaining the integrity of the
intestine [13]. As shown in the result, no association was
found.
IL 10 was originally described as cytokines synthesis
inhibitory factor because of its ability to inhibit the pro-
duction of IL 2, IL 3, interferon gamma (INF-g), and gran-
ulocyte-macrophage colony stimulating factor (GM-CSF) by
Th1 clones [34]. An elevated IL 10 level has been described
to be related to systemic lupus erythematosus, asthma, and
susceptibility to infectious diseases [35]. A liver protection
effect has been reported with elevated IL 10 level through
the activation of STAT3 in Kupffer cells/macrophages and
the subsequent inhibition of liver inflammation [32]. The
frequently studied polymorphisms in the promoter region of
IL 10 are e1082 G>A, e819 C>T, and e592 C>A. Because IL
10 e819 C>T and IL 10 e592 C>A are in complete linkage,
we did not genotype the latter. Our results showed that
both IL 10 e1082 G>A and IL 10 e819 C>T had considerably
low p values (p Z 0.026 and p Z 0.031, respectively) in
comparison with the healthy control group, and the p
values in comparison to pancreatitis controls were also low.
Although the p value did not reach statistical significance
(p < 0.01), the caseecontrol OR of people with G allele in
e1082 G>A was 0.124 (95% CI, 0.015e0.997) in healthy
controls and 0.106 (95% CI, 0.013e0.912) in pancreatitis
controls; this implied that people carrying a G allele in this
locus were less likely to develop alcoholic liver cirrhosis. By
contrast, with the presence of T allele in IL 10 e819 C>T,
the reference OR in healthy controls became 6.233 (95% CI,
0.739e52.547) in the CT genotype and 10.521 (95% CI,
1.252e88.440) in the TT genotype; a similar trend was also
noted in pancreatitis controls. This result implied that
people with T alleles were prone to develop alcoholic livercirrhosis. A study conducted by Sua´rez et al. [33] found that
IL 10 mRNA expression is higher in IL 10 e1082 G allele, and
the serum IL 10 is higher in GG genotype. However, no
definite promoter activity studies regarding IL 10 e819 C>T
were found, and the studies on its complete linkage locus IL
10 e592 C>A showed controversial results [36,37]. In
comparison with our result, we supposed that people with
G allele in IL 10 e1082 and C allele in IL 10 e819/e592 may
have a good defense against alcoholic liver cirrhosis and the
gene expression may be higher.
Because of linkage disequilibrium, only three haplotypes
were found on IL 10 promoter polymorphisms: ACC (H1),
ATA (H2), and GCC (H3) [17]. A previous study using lucif-
erase reporting assay concluded that the H3 construct
conferred a stronger transcriptional activity than H2 [38].
There was a study carried out in Northern Spain to quantify
by reverse transcription-PCR the mRNA extracted from 128
healthy Caucasian individuals [37]. The study showed
significantly increased levels of mRNA expression for in-
dividuals carrying the H3/H3 diplotype, compared to H2/H2
(p Z 0.016) or H2/H1 (p Z 0.01). As far as liver disease is
concerned, one IL 10 haplotype (ACC, H1 haplotype) has
been reported to be associated with increased risk of he-
patocellular carcinoma progression in patients with chronic
hepatitis B [17]. However, the haplotype reported above is
not significant in the current study. In our study, as shown
in Table 3, the p value of carrying an H1 haplotype or not
was not significant in both control groups. However, in
participants carrying an H3 haplotype or not, the p value
between case and healthy controls was 0.027 (p < 0.05)
and the OR was 0.124 (95% CI, 0.015e0.997), and the rate
was even lower in pancreatitis controls. By contrast, in
participants with zero, one, and two H2 haplotypes,
p Z 0.031 (p < 0.05) in healthy controls and p Z 0.028
(p < 0.05) in pancreatitis controls. Using people without H2
haplotype as the reference diplotype, the OR of other/H2
diplotype was 6.233 (95% CI, 0.739e52.547) and the OR of
H2/H2 was 10.521 (95% CI, 1.252e88.440) in healthy con-
trols, and this was 6.588 (95% CI, 0.727e59.679) in
pancreatitis controls with other/H2 diplotype and 12.833
(95% CI, 1.408e117.008) in pancreatitis controls with H2/
H2 diplotype. Our results implied that people with H3
haplotype were less likely to develop alcoholic liver
cirrhosis and people who have H2 haplotype were prone to
develop alcoholic liver cirrhosis. Because the H3 haplotype
may be with the strongest transcriptional activity and H2
may be the weakest, higher IL 10 concentrations in the
liver may confer a protective effect against alcohol-related
damage. Our result suggested that IL 10 promoter haplo-
type polymorphisms were associated with alcoholic liver
cirrhosis.
The mechanism of alcoholic liver damage has been
widely studied, and several factors have been proposed.
However, the differences in genetic background between
individuals are rarely discussed. In this study, we found IL
10 promoter haplotypes to be associated with alcoholic
liver cirrhosis. Nevertheless, we believe that other genetic
factors may influence the pathogenesis of the disease. We
reasoned that a genome-wide association study will be
beneficial. A better understanding of the genetic back-
ground of alcoholic liver cirrhosis may advance the pre-
vention and treatment of the disease.
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